Switzerland covid-19 outbreak pandemic patient Switzerland

Memo Therapeutics discovers neutralising antibodies against Covid-19

Reading now: 374
www.pharmaceutical-technology.com

Switzerland-based Memo Therapeutics has discovered multiple SARS-CoV-2 neutralising antibodies with the potential for development as immunotherapy against Covid-19.

Since March, the company has selected certain donors from Covid-19 patients in the country. The selection criteria was for patients who had a clinical course of the disease indicative of a potent antibody response.

Memo Therapeutics collected blood samples from the selected donors and used its microfluidic DROPZYLLA discovery platform to find virus-neutralising antibodies.

The platform is designed to allow the production of complete recombinant human antibody repertoires. It is said to preserve all characteristics present in each patient’s B cells.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA